Daily market recaps with key events, stock movements, and global influences Bhavneesh Sharma MBBS, MD, MBA (Finance) @bs2537 Capricorn’ $CAPR deramiocel (CAP-1002) is the only allogeneic cell therapy in FDA review for DMD, repeat-dosed and genotype-agnostic. Uniquely tackles cardiomyopathy—the #1 killer in DMD— with durable 3-year functional and cardiac benefits.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by AI-Designed Capsids
IN8bio Phase 1 Patient Achieves 4-Year Remission in Glioblastoma Trial; $INAB Stock Drops 8.2%
5 posts • GPT (4.1 mini) Published Jun 10, 2025, 11:47 PM IN8bio announced that a patient treated with its INB-200 gamma-delta T-cell therapy in a Phase 1 glioblastoma trial has remained in remission for four years. This milestone demonstrates sustained clinical benefit from the therapy in treating glioblastoma, a form of brain cancer. The company highlighted this achievement as a significant development in its ongoing clinical program.
FDA Opens Accelerated Approval for Avidity’s Del-Brax in FSHD After Positive Phase 1/2 Data, Initiates Phase 3 Study
Daily market recaps with key events, stock movements, and global influences 7 posts • GPT (4.1 mini) Updated Jun 10, 2025, 02:22 AM Avidity Biosciences has announced that the U.S. Food and Drug Administration (FDA) has opened an accelerated approval regulatory pathway for its drug Del-Brax, targeting facioscapulohumeral muscular dystrophy (FSHD). Concurrently, Avidity has initiated the global, confirmatory Phase 3 FORWARD™ study for FSHD.
Avidity Biosciences Reports Positive Phase 1/2 Data, FDA Clears Accelerated Approval Pathway for Del-Brax in FSHD
4 posts • GPT (4.1 mini) Published Jun 9, 2025, 12:20 PM Avidity Biosciences has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the company to pursue accelerated approval for Del-Brax, its investigational treatment for facioscapulohumeral muscular dystrophy (FSHD). Concurrently, Avidity has initiated the global, confirmatory Phase 3 FORWARD™ study for Del-Brax in FSHD patients.
FDA's CBER Hosts June 5 Cell and Gene Therapy Roundtable with Secretary Kennedy, Featuring Special Recording Setup
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published Jun 5, 2025, 02:53 PM The Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) hosted a roundtable on cell and gene therapy on June 5, 2025, from 9 a.m. to 12 p.m. The event was conducted with special lighting, multiple cameras, and a photographer to facilitate recording.
Regenxbio Shares Rise 4.2% on Positive Phase I/II AFFINITY Duchenne Trial Data for RGX-202 Using AAV8 Vector
5 posts • GPT (4.1 mini) Published Jun 5, 2025, 12:11 PM Regenxbio Inc. reported new positive functional data from its ongoing Phase I/II AFFINITY Duchenne trial evaluating RGX-202, an experimental gene therapy targeting Duchenne muscular dystrophy. The interim results indicate that children with this severe muscle disorder experienced improved control of their bodies following treatment. The therapy utilizes an AAV8 vector combined with a C-terminal microdystrophin construct.
uniQure Reaches FDA Alignment on AMT-130 Statistical Plan, CMC Info, Accelerated Approval Ahead of 2026 BLA
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published Jun 2, 2025, 01:58 PM uniQure NV has announced regulatory progress for its gene therapy candidate AMT-130, designed to treat Huntington’s disease. The company has reached alignment with the U.S. Food and Drug Administration (FDA) on several key aspects of the statistical analysis plan and Chemistry, Manufacturing, and Controls (CMC) information.
FDA Halts Rocket Pharma’s Phase II RP-A501 Danon Disease Gene Therapy Trial After Patient Death
Daily market recaps with key events, stock movements, and global influences 28May: What does @RocketPharma suspect may have led to the death of a patient dosed with its Danon disease gene therapy candidate RP-A501 in a pivotal trial? And how did three analysts respond to the news?
Intellia Shares Fall 25% After Grade 4 Liver Event in MAGNITUDE Trial for ATTR-CM Gene Therapy
Daily market recaps with key events, stock movements, and global influences 11 posts • GPT (4.1) Updated May 29, 2025, 04:39 PM Intellia Therapeutics disclosed in a regulatory filing that a participant in its ongoing Phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) experienced a grade 4 elevation in liver enzymes (ALT and AST), indicating severe liver stress.
Biohaven's BHV-1510 Plus Cemiplimab, First-in-Class FGFR3 ADC, and Degrader Data Featured at ASCO 2025
Daily market recaps with key events, stock movements, and global influences 15 posts • GPT (4.1) Updated May 28, 2025, 10:45 PM Biohaven Ltd. presented updates from its oncology and immunology programs at its 2025 R&D Day, coinciding with the ASCO 2025 Annual Meeting. The company highlighted preliminary clinical data for its antibody drug conjugates (ADCs) and protein degrader platforms.
Biogen, City Therapeutics Launch $1B RNAi CNS Partnership With $16M Upfront, $30M Investment, Option for More Targets
Daily market recaps with key events, stock movements, and global influences 17 posts • GPT (4.1) Updated May 28, 2025, 08:38 PM Biogen Inc. and City Therapeutics have announced a strategic research collaboration to develop novel RNA interference (RNAi)-based therapies, initially targeting central nervous system (CNS) diseases. The partnership leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's drug development expertise.
Biogen and CityTx Announce $46M Upfront, $1B RNAi CNS Therapy Deal as Aurion Withdraws IPO
Daily market recaps with key events, stock movements, and global influences 8 posts • GPT (4.1 mini) Updated May 28, 2025, 02:16 AM Biogen and CityTx have announced a new research collaboration to develop select novel RNA interference (RNAi)-based therapies targeting the central nervous system (CNS). The partnership includes an upfront payment of $46 million to CityTx and has a potential total deal value exceeding $1 billion.
FDA Places Clinical Hold on Rocket Pharmaceuticals' RP-A501 Danon Disease Trial After Patient Death From Capillary Leak Syndrome, Shares Drop 60% | DeepNewz Stocks
Daily market recaps with key events, stock movements, and global influences 26 posts • GPT (4.1 mini) Updated May 27, 2025, 08:57 PM Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Phase 2 pivotal trial of RP-A501, a gene therapy for Danon disease, following the death of a patient. The patient experienced serious adverse events related to capillary leak syndrome and subsequently died from acute systemic infection.
Biogen and City Therapeutics Partner on CNS RNAi Therapies with $46M Upfront; BrainStorm, Aurion Also Make Moves
Daily market recaps with key events, stock movements, and global influences 10 posts • GPT (4.1 mini) Updated May 27, 2025, 08:06 PM Biogen and City Therapeutics have announced a strategic research collaboration focused on developing select novel RNA interference (RNAi)-based therapies. The partnership includes a $46 million upfront payment and could exceed $1 billion in total deal value, targeting central nervous system (CNS) conditions.
Lexeo Therapeutics Raises $80 Million Led by Frazier and Janus to Advance Cardiovascular Genetic Medicines with AAVrh10 Vector
GlycoEra Grabs $130M Series B to Make Extracellular Degraders for Autoimmunity. (Sub. Req). https://t.co/3wFj5FJaf2 $LXEO with a likely safer AAVrh10 vector that uses lower viral dose than $RCKT AAV9.
FDA Halts Rocket Pharma Danon Disease Trial After Patient Death; Stock Drops Over 60%
Daily market recaps with key events, stock movements, and global influences 13 posts • GPT (4.1) Updated May 27, 2025, 12:43 PM Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Phase 2 pivotal trial of RP-A501, an investigational gene therapy for Danon disease (NCT06092034). The hold follows a serious adverse event (SAE) in one patient, which involved clinical complications related to capillary leak syndrome.
Biogen and City Therapeutics Ink $46M RNAi Deal Worth Over $1B; BrainStorm Partners with Minaris for NurOwn® ALS Trials
5 posts • GPT (4.1 mini) Published May 27, 2025, 12:15 PM BrainStorm Cell Therapeutics has secured a key manufacturing partnership with Minaris to support its upcoming NurOwn® Phase 3b clinical trials for amyotrophic lateral sclerosis (ALS). In a separate development, Biogen and City Therapeutics announced a strategic research collaboration to develop select novel RNA interference (RNAi)-based therapies, leveraging City Therapeutics' next-generation RNAi engineering technologies.
24 posts • GPT (4.1 mini) Published May 24, 2025, 05:17 AM Researchers have introduced MMaDA, a novel class of multimodal diffusion foundation models developed by ByteDance, designed to excel in textual reasoning, multimodal understanding, and text-to-image generation. MMaDA surpasses existing models such as LLaMA-3-7B, Qwen2-7B, SDXL, and Janus by employing a unified diffusion architecture with a shared probabilistic formulation and mixed long chain-of-thought fine-tuning.
NIH-Funded Researchers Develop AAV and CRISPR-TO Gene Delivery Systems for Brain and Spinal Cord Cells
Daily market recaps with key events, stock movements, and global influences 15 posts • GPT (4.1 mini) Published May 23, 2025, 11:31 AM Researchers have developed advanced genetic tools and gene delivery systems that enable precise targeting and treatment of brain and spinal cord cells.
London Calling 2025 Highlights Oxford Nanopore Sequencing Advances with 200 Gb Flow Cells and Disease Applications
Daily market recaps with key events, stock movements, and global influences 5 posts • GPT (4.1 mini) Published May 21, 2025, 07:11 PM The Nanopore Conference 2025, also known as London Calling 2025, is currently underway at Old Billingsgate, London, featuring a series of masterclasses and talks focused on Oxford Nanopore sequencing technology.
AMVUTTRA Shows Benefits in HELIOS-B; Intellia Nex-z Phase 1 Data and Piper NKTR REZOLVE-AD June 2025 Update at ASGCT
6 posts • GPT (4.1 mini) Published May 19, 2025, 04:50 AM Recent data from the HELIOS-B trial indicate that AMVUTTRA® (vutrisiran) significantly reduces mortality and various cardiovascular events in patients with ATTR amyloidosis with cardiomyopathy, highlighting its therapeutic potential.
Rocket Pharmaceuticals Shows PKP2 Protein Increase with RP-A601 in PKP2-ACM at ASGCT; Analysts Raise Price Targets
6 posts • GPT (4.1 mini) Published May 16, 2025, 08:16 PM At the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in May 2025, several biotechnology companies presented advancements in gene therapy and vector technology. Latus Bio unveiled a new AAV-Ep+ capsid variant capable of unprecedented protein production in the brain.
Absci Doses First Participants in Phase 1 Trial of Anti-TL1A AI-Designed Crohn's Disease Drug ABS-101 with 10.8% Pre-Market Gain
6 posts • GPT (4.1 mini) Published May 15, 2025, 10:20 PM Absci Corporation has initiated dosing of the first participants in the Phase 1 clinical trial of ABS-101, a potential best-in-class anti-TL1A antibody designed for the treatment of inflammatory bowel disease, including Crohn's disease. This milestone marks Absci's transition into a clinical-stage biotech company, highlighting the use of generative AI in drug discovery.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with AI-Designed
Contact AI-Designed, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack